Evolving Our Partnership: The CSER2 Centralized Support Coordinating Center

发展我们的合作伙伴关系：CSER2 集中支持协调中心

• 批准号: 10360348
• 负责人: Stephanie Malia Fullerton
• 金额: $ 92.52万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10360348
• 关键词: Clinical; Clinical effectiveness; Effectiveness; Family member; Genomic medicine; Genomics; Goals; Individual; Logistics; Outcome; Patients; Phase; Physicians; Population; Recommendation; Research; Site; Time; Work; clinical sequencing; evidence base; experience; success; synergism

Abstract The overall goal in this competitive renewal proposal for the Clinical Sequencing Exploratory Research (CSER) Consortium coordinating center (CC) is to enhance the effectiveness of the next CSER phase (CSER2) by assuring the effective coordination and logistic support needed to propel cross-consortium efforts and to identify new synergies that increase the scientific value of the individual projects. CSER2 will continue to generate the evidence base required for clinical genomic medicine, expanding its reach into non-academic centers and enhancing the diversity of the patient groups. It will provide timely, pragmatic information about best practices for genomic medicine that permit optimal provide useful and accessible recommendations for physicians, patients, family members, and policymakers. In approaching this task, we will leverage our considerable experience as the existing CSER CC and as partners in many other genomics consortia, including expertise in diverse and non-academic populations to facilitate the work of CSER2. In the current cycle of CSER (CSER1) the UW CC has made numerous significant contributions to the important work of CSER, as outlined in the progress section. Our success is underscored by the fact that the PIs at every CSER1 UO1 site support UW continuing as the CSER2 CC.

摘要 临床测序探索性研究竞争性更新提案的总体目标 (CSER)联合体协调中心(CC)是为了提高下一阶段CSER的有效性 (CSER2)确保推动跨财团所需的有效协调和后勤支持 努力，并确定新的协同作用，以增加个别项目的科学价值。CSER2 将继续产生临床基因组医学所需的证据基础，扩大其覆盖范围 向非学术中心转移，增强患者群体的多样性。它将及时提供， 有关基因组医学最佳实践的实用信息，可提供有用和 为医生、患者、家庭成员和政策制定者提供可访问的建议。在接近中 在这项任务中，我们将利用我们作为现有CSER CC和作为 许多其他基因组学联盟，包括在不同的和非学术群体中的专业知识，以促进 CSER2的工作。在当前的CSER(CSER1)周期中，UW CC取得了许多重大进展 对CSER重要工作的贡献，如进度部分所述。我们的成功在于 每个CSER1 UO1站点的PI支持UW继续作为CSER2 CC这一事实突显了这一点。